The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Menarini Group and Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, will present updated results from phase Ib/II ELECTRA and ELEVATE clinical studies evaluating elacestrant (Orserdu) in combination with other treatments at the 2024 American Society of Clinical Oncology on June 2. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Tecvayli + Talvey, Talvey + pomalidomide show significant survival benefit in earlier-line r/r MM, phase III trial shows

Two drug combinations, Tecvayli (teclistamab-cqyv) + Talvey (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and Talvey + pomalidomide (Pomalyst, sponsored by Bristol Myers Squibb), demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with investigator’s choice standard of care for adult patients with relapsed or refractory multiple myeloma who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide. 
Clinical Roundup

Hormone produced by the thymus may reduce age-related inflammation and improve cancer outcomes, USC preclinical study finds

Chronic, low-grade inflammation in the body—a phenomenon known as “inflammaging” because it increases with age—has been linked to many leading causes of illness and death, including cancer, heart disease, metabolic conditions, and neurodegenerative diseases. But scientists have struggled to understand what causes inflammaging or how to reverse its effects.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account